ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

ClinicalTrials.gov ID: NCT02986854

Public ClinicalTrials.gov record NCT02986854. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Healthy Individuals 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Study identification

NCT ID
NCT02986854
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
704 participants

Conditions and interventions

Interventions

  • Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo) Biological

Biological

Eligibility (public fields only)

Age range
15 Years to 55 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 7, 2016
Primary completion
Jul 16, 2017
Completion
Dec 6, 2017
Last update posted
Nov 24, 2019

2016 – 2017

United States locations

U.S. sites
36
U.S. states
16
U.S. cities
30
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35211
GSK Investigational Site Huntsville Alabama 35802
GSK Investigational Site Chandler Arizona 85224
GSK Investigational Site Anaheim California 92804
GSK Investigational Site Roseville California 95661
GSK Investigational Site Sacramento California 95815
GSK Investigational Site Sacramento California 95864
GSK Investigational Site San Jose California 95119
GSK Investigational Site Centennial Colorado 80112
GSK Investigational Site Littleton Colorado 80128
GSK Investigational Site Pinellas Park Florida 33781
GSK Investigational Site West Palm Beach Florida 33409
GSK Investigational Site Boise Idaho 83712
GSK Investigational Site Chicago Illinois 60604
GSK Investigational Site Wichita Kansas 67205-1138
GSK Investigational Site Bardstown Kentucky 40004
GSK Investigational Site Louisville Kentucky 40207
GSK Investigational Site Omaha Nebraska 68114
GSK Investigational Site Omaha Nebraska 68134
GSK Investigational Site Omaha Nebraska 68144
GSK Investigational Site Binghamton New York 13901
GSK Investigational Site Raleigh North Carolina 27609
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Cleveland Ohio 44121
GSK Investigational Site Charleston South Carolina 29407
GSK Investigational Site Fort Worth Texas 76135
GSK Investigational Site Plano Texas 75024
GSK Investigational Site Plano Texas 75093
GSK Investigational Site San Angelo Texas 76904
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Tomball Texas 77375
GSK Investigational Site Draper Utah 84020
GSK Investigational Site Salt Lake City Utah 84109
GSK Investigational Site Salt Lake City Utah 84121
GSK Investigational Site Salt Lake City Utah 84123
GSK Investigational Site South Jordan Utah 84095

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02986854, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 24, 2019 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02986854 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →